Tradestie Institutional Equity Comparison Engine

LCTX vs DBVT โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-19 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

LCTX Overall Edge

LCTX Captures Institutional Edge (3โ€“1 Pillars ยท 6โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Lineage Cell Therapeutics, Inc. (LCTX) driven by superior Valuation, Growth & Margin, Momentum & Technical while DBVT counters with relative strength in Options & Structure. Fundamentally, LCTX trades at 30.7x Forward P/E with -280.3% operating margin (-61.0% YoY revenue) versus DBVT at N/M Forward P/E and -5577.0% operating margin (-42.9% YoY). In options structure, LCTX sits in BREAKDOWN (100th %ile IV; Dealer Gamma Walls on Pro) against DBVT sits in SURGE (13th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner LCTX
LCTX 30.7x vs DBVT N/M Fwd P/E
Growth & Margin Winner LCTX
Op Margin -280.3% vs -5577.0% ยท YoY -61.0% vs -42.9%
Momentum & Technical Winner LCTX
1Y -53.7% vs -32.4% ยท 52W Pos 4% vs 4%
Options & Structure Winner DBVT
BREAKDOWN (100th %ile IV) vs SURGE (13th %ile IV)
LCTX NYSE American
Lineage Cell Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$0.82
-2.21% 1D
Market Cap $212.1M
1M Return -13.82%
1Y Return -53.67%
Forward P/E 30.7x
Unified AI Score
58.9 / 100 HOLD
Tech 65.0 Fund 54.0 Flow 65.0 Mom 45.0
DBVT NASDAQ
DBV Technologies S.A.
Biological Products, (No Disgnostic Substances)
$9.42
-2.69% 1D
Market Cap $619.6M
1M Return -2.08%
1Y Return -32.38%
Forward P/E N/M
Unified AI Score
43.0 / 100 HOLD
Tech 45.0 Fund 51.0 Flow 60.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: LCTX -53.67% DBVT -32.38% Spread: +21.29 pp (DBVT Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period LCTX Revenue DBVT Revenue LCTX Op. Margin DBVT Op. Margin Margin Edge
FY2018 $0M N/A -837.9% N/A LCTX
FY2019 $0M $10M -1106.0% -1162.8% LCTX
FY2020 $0M $10M -1448.4% -1408.7% DBVT
FY2021 $0M $10M -1133.6% -1727.6% LCTX
FY2022 $10M $0M -153.2% -1994.9% LCTX
FY2023 $10M $20M -276.5% -486.0% LCTX
FY2024 $10M $0M -226.1% -2808.7% LCTX
FY2025 $10M $10M -251.6% -2609.2% LCTX

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: LCTX (6) vs DBVT (3)
Institutional Metric LCTX DBVT Criterion Row Winner
Market Capitalization Scale $212.1M $619.6M Larger Scale DBVT
Trailing P/E Ratio Valuation 30.7x N/M Lower Multiple LCTX
Forward P/E Ratio Valuation 30.7x N/M Lower Multiple LCTX
Revenue Growth (YoY) Growth -61.0% -42.9% Higher Growth DBVT
Operating Margin (TTM) Profitability -280.3% -5577.0% Higher Margin LCTX
Net Profit Margin Profitability 16.2% 0.0% Higher Margin LCTX
Return on Equity (ROE) Capital Efficiency 4.3% -205.8% Higher ROE LCTX
52-Week Range Position Momentum 4% ($1โ€“$2) 4% ($9โ€“$26) Stronger Trend Tie
Beta / 30D Volatility Risk Regime 1.36ฮฒ ยท 79% Vol 1.19ฮฒ ยท 75% Vol Lower Realized Risk DBVT
Unified Institutional Score Composite Signal 58.9 / 100 (HOLD) 43.0 / 100 (HOLD) Higher Composite LCTX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full LCTX vs DBVT Buy Guide
LCTX BREAKDOWN
6d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live LCTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
DBVT SURGE
6d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 13th %ile
IV Regime Compressed (<25th %ile)
Live DBVT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither LCTX nor DBVT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.